Using K562 cell line, we report that STATIP1 may act as a negative regulator of STAT3 transcriptional activity in CML and reduce the effects of Imatinib (IM) in K562 cells. This evidence concerns the gene STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive.